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CLINICAL RELEVANCE
Prostate cancer-induced bone metastasis is incurable as patients ultimately develop resistance to current therapies. Prostate cancer interaction with the bone microenvironment uniquely favors osteoblastic lesion development. The mechanisms that promote osteoblastic metastasis are not fully understood and this information is required to develop better therapeutic approaches. We identified Notch3-dependent induction and secretion of MMP-3 as new axis in prostate cancer bone metastases. Notch3 and MMP-3 are co-upregulated in human prostate cancer bone metastases, where they promote osteoblastic lesions by suppressing osteoclast differentiation and enhancing osteoblastogenesis. This study provides evidence, for the first time, of a newly identified Notch3-MMP-3 axis that promotes prostate cancer-induced lesion development, which could be used as a therapeutic target for inhibiting osteoblastic bone metastasis.
INTRODUCTION
Prostate cancer is the most common non-skin cancer in males, and second leading cause of mortality, with death primarily due to metastasis (1, 2) . Prostate cancer invariably metastasizes to the bone and forms osteoblastic (bone-forming) lesions. Such lesions cause severe bone pain, fractures, bone deformity, hypercalcemia, and immunological complications (1, 3) . Even though prostate cancer metastasis is typically osteoblastic, markers of bone turnover indicate that underlying osteolytic events are also involved (4, 5) . Death from metastatic bone disease is due in part to the lack of effective therapy, the development of which requires knowing the mechanisms that control this mixed blastic/lytic phenotype.
Bone, a dynamic connective tissue, is constantly remodeling during an individual's lifetime. Remodeling depends on two cells types, osteoblasts and osteoclasts, both of which work in harmony to maintain normal bone. Osteoblasts, derived from mesenchymal stem cells, make new bone. Osteoclasts, derived from monocytes, degrade bone. During osteoblastic metastasis, the bone remodeling balance favors bone formation, i.e. osteoblastogenesis (1, 6) . (7) (8) (9) . Majority of the studies investigating normal prostate gland development and prostate cancer have focused on Notch1.
In the normal prostate, Notch1 is required for basal cell maintenance, luminal progenitor proliferation, and branching morphogenesis (10, 11) . In prostate cancer, knockdown of Notch1 5 inhibits invasion, decreases growth, suppresses colony formation in vitro, and increases chemosensitivity (12, 13) . Elevated Notch1 staining is observed in aggressive prostate tumors relative to prostatic intraepithelial neoplasia and normal tissue (12) . These data suggest Notch1 may be a driver of prostate cancer progression.
Recent studies demonstrate that Notch3 is also involved in normal prostate development where it is required for luminal cell differentiation (11, 14, 15) . Furthermore, elevated Notch3 expression positively correlates with prostate cancer progression, recurrence, and drug resistance (16) (17) (18) (19) (20) . In metastatic breast cancer, Jag-1 in tumor cells activates Notch signaling in osteoblasts to stimulate osteoclastogenesis in osteolytic bone lesions, while Notch3 is induced in tumor cells by osteoblasts (21, 22) . However, the role of Notch3 in cancer cells and its influence on osteolytic versus osteoblastic disease remains unknown.
Matrix metalloproteinases (MMPs) are a family of proteases secreted by stromal and tumor cells whose expression is a prerequisite for tumor progression. MMPs are increased in many cancers and negatively correlated with patient survival (23) . MMP-1, 3, 7 and 9 reportedly promote prostate cancer metastasis to the bone (5). Both MMP mRNA and protein are elevated in serum and tissue samples from prostate cancer patients and is correlated with advanced and metastatic disease (23) . Polymorphisms in MMP-3 predict for increased prostate cancer risk and MMP-3 levels are elevated specifically in patients with bone metastases (24, 25) . MMP-1, 9, and 13 are required for bone resorption, and MMP-9 promotes osteoclast polarization and ruffled border formation (5) . Although Notch1 reportedly promotes the expression of MMP-9 (12), it is unknown whether Notch3 contributes to the expression of MMPs or which ones.
During our studies, we observed elevated Notch3 expression in human prostate cancer bone metastases and hypothesized that Notch3 promotes bone metastasis by remodeling the bone microenvironment. Herein, we report that Notch3 contributes to osteoblastic bone metastasis by suppressing osteoclasts and stimulating osteoblastogenesis through induction of MMP-3.
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MATERIALS AND METHODS
Cells lines and animals
PC3 and 22Rv1 cells were obtained from ATCC, and C4-2B cells was obtained from Dr.
Robert Sikes (University of Delaware) (26) . All lines were maintained in RPMI1640 (Gibco) supplemented with 10%FBS (Gemini). All lines were validated by STR analysis and periodically checked for mycoplasma contamination using MycoAlert PLUS kit (Lonza). Conditioned medium was collected by starving sub-confluent cells for 24 h in α-MEM (Gibco).
The 5-6 week old male NSG mice used in this study were bred and maintained in a pathogen-free and ALAAC-certified barrier facility following guidelines from VARI Institutional Animal Care and Use Committee and the Department of Defense (DOD) Animal Care and Use Committee.
Doxycycline-inducible shRNA and NICD
Doxycycline-inducible shRNA targeting Notch3 was generated as previously described (14, 27) . Doxycycline-inducible NICD1 was PCR subcloned from EF.hICN1.CMV.GFP into pENTR3C (Invitrogen) between SalI and NotI sites, creating pENTR3C-NICD1, using the following primers: Fwd 5'-AATTGTCGACCCAAGCTGGCTAGTTAAGC-3', Rev 5'-TTAAGCGGCCGCTTTATTCCAGCACACTGGCGGC-3'. EF.hICN1.CMV.GFP was a gift from Linzhao Chen (Addgene plasmid #17623) (28) . Cloned inserts were amplified with Syzygy SyFi high fidelity polymerase (Integrated Scientific Solutions, SY-100) and ligated with LigateIT rapid ligase (Affymetrix). Doxycycline inducible NICD3 was PCR subcloned from pCLE-NICD3 into pENTR3C between SalI and NotI, creating pENTR3C-NICD3, using primers:
pCLE-NICD3 was a gift from Nicholas Gaiano (Addgene plasmid #26894) (29) .
pENTR3C-NICD1 and pENTR3C-NICD3 were recombined via L/R Clonase II (Thermo) into pLenti-CMV-Puro-DEST (w118-1) to make pLenti-Tet-NICD1-Puro and pLenti-Tet-NICD3-Puro. Medium was changed to serum-starved medium for the last 24 h of culture. TRAP staining was performed according to manufactures protocol (Sigma Aldrich). TRAP-positive multinucleate (2 > nuclei/cell) osteoclasts were counted in 10 random fields under 20x magnification.
Osteoblast proliferation was evaluated via MTT assay with cells plated in triplicate using the manufacturers protocol (ATCC). In a subset of assays, cultured osteoblasts or osteoclasts were treated with recombinant human MMP-3 (Abcam).
Histology and immunohistochemistry
Mouse tibiae were harvested and fixed in 10% neutral-buffered formalin (Sigma) for 4 d at 4 °C, followed by decalcification in 14% EDTA for 5-6 d at 4 °C, and then embedded in paraffin.
Serial bone sections 5 μm thick were used for lHC staining. Hematoxylin and eosin (H&E) and TRAP staining were done as previously reported (31) . Paraffin embedded sections were stained using antibodies against Ki67 (1:100; Thermo Scientific; RM-9106), MMP-3 (1:100;
Abcam; ab52915), or Notch3 (1:300; Santa Cruz; sc5593).
TRAP and Ki67 quantification
Serial sections stained for TRAP were scanned and images collected using Aperio software. TRAP-positive multinucleate osteoclasts (2 > nuclei/cell) at the bone/tumor interface were counted at 20X magnification. Ki67 was quantified by counting three-four random fields under 40X magnification. All counting was blinded.
TMA staining and quantification
Tissue microarray (TMA) sections having patient-matched visceral and bone metastasis 
Protein extraction, immunoblot, ELISA, and cytokine array
Mouse tibiae and subcutaneous tumors were snap-frozen in liquid nitrogen. Frozen tibiae were homogenized in RIPA buffer (32) using a FastPrep-24 tissue homogenizer (MP Biomedicals). Prostate cancer cell lines were lysed using RIPA buffer as described previously 10 (32). Total protein (10-20 μg) was separated by SDS-PAGE and transferred to PVDF membranes (Fisher). Membranes were blocked with 5% BSA-TBST and incubated with antibodies diluted in 5% BSA-TBST as previously described (32) . Primary antibodies were detected using HRP-conjugated secondary antibodies (Sigma) by chemiluminescence using Quantity One imaging software on a Bio-Rad Gel Docking system. Antibodies listed in Supplementary Table S1 .
Equal amounts of protein from subcutaneous or tibiae tumors pooled from two mice were incubated with a 174 protein spotted human cytokine antibody array C2000 (Ray Biotech Inc) according to the manufacturer's protocol.
MMP-3 ELISA (R&D) was performed on 24 h serum-starved PC3-NICD3 cells treated with or without doxycycline. Media were collected and concentrated (Ultracel-10k;Millipore) and equal amounts were used to quantify total MMP-3.
RNA extraction and qRT-PCR
Total RNA was extracted from frozen tibiae or cell lines using TRIzol (Invitrogen, Carlsbad, CA). Equal amounts of RNA were reverse transcribed through the SuperScript firststrand synthesis system (Invitrogen) and qRT-PCR was performed using SYBR Green Supermix (Bio-Rad, Hercules, CA) on Applied BioSystems. Primers were synthesized by Integrated DNA Technologies (IDT, Coralville, IA) and the levels of target mRNAs were standardized to GAPDH and plotted as Log2-fold. Primers listed in Supplementary Table S2 .
Statistical analysis
All statistical analysis on the mice with one or two comparison groups used Student's ttest and in experiments where more than two groups were being compared, ANOVA was used.
In all statistical analyses the two-tailed significance is reported. For biostatistical analysis of the TMAs, multivariate analysis of Notch3 and MMP3 expression levels in visceral versus bone metastases was conducted using mixed effect models. The mixed effect models accounted for the correlation between the measurements obtained across multiple observations per individuals. Spearman correlation was used to calculate correlation between MMP-3 and Notch3 expression across all tissues.
RESULTS
Notch3 inhibits osteolytic bone lesion development.
Prostate cancer cells, which promote osteolytic (PC3) or mixed (blastic/lytic) lesions (C4-2B and 22Rv1), were assayed for Notch1 and Notch3 expression by qRT-PCR and immunoblotting. Both Notch1 and Notch3 mRNAs were higher in the osteoblastic lines, C4-2B and 22Rv1, relative to the lytic PC3 cells (Fig. 1A-B ). Notch3 mRNA expression was 2-3-fold higher than Notch1. Notch1 and Notch3 protein paralleled the increase in mRNA (Fig.1C-D) .
Thus, Notch might play a role in osteoblastic lesion development.
Osteolytic PC3 cells were engineered to express doxycycline-inducible Notch3 intracellular domain, NICD3. PC3-NICD3 cells were injected into mouse tibiae and mice fed sucrose as controls or doxycycline to induce NICD3 expression. Radiographic imaging after 3 weeks showed the expected osteolytic lesion development in control PC3-NICD3-injected tibiae (Fig. 1E) . Induction of NICD3 by doxycycline significantly reduced osteolytic lesion area ( Fig   1E) . H&E staining validated tumor growth in the bone, and IHC staining confirmed NICD3 induction in the doxycycline-treated tumors (Fig. 1F ).
PC3 cells engineered to induce NICD1, did not produce any significant changes in osteolytic lesion area when injected tibial tumors were stimulated with doxycycline ( Supplementary Fig. S1A ). The observed changes in lesion area were not due to non-specific effects of doxycycline, as doxycycline treatment of mice injected with non-NICD expressing tumors did not alter osteolytic lesion formation ( Supplementary Fig. S1B ). Thus, specific induction of NICD3, but not NICD1, reduces osteolytic lesion formation in prostate tumors in the bone.
To determine whether the decrease in osteolytic lesion development by NICD3 was due 12 to changes in tumor proliferation, we monitored Ki67 expression by IHC staining. There was no difference in proliferation between PC3 control and PC3 NICD3-expressing tumors ( Supplementary Fig. S2A ). To assess the effects of Notch3 on the bone microenvironment, we quantified the number of TRAP-positive osteoclasts. There was over a 2-fold decrease in the number of TRAP-positive osteoclasts at the tumor-bone interface in doxycycline-treated PC3-NICD3 tumors compared to sucrose-treated tumors (Fig. 1F) . Thus, the effect of NICD3 is on the tumor microenvironment, rather than an intrinsic effect on tumor growth.
Blocking Notch3 increases osteolytic lesions.
To determine if loss of Notch3 enhances osteolysis, we injected PC3 cells harboring doxycycline-inducible Notch3 shRNA (PC3-shN3) into mouse tibiae. PC3-shN3 doxycyclinetreated tumors had significantly more lytic lesion area compared to sucrose-treated control tumors (Fig. 1G) . Loss of Notch3 expression by doxycycline treatment was validated by IHC (Fig. 1H) . There was no change in tumor proliferation ( Supplementary Fig. S2B ) and the doxycycline-treated PC3-shN3 tumors had significantly more TRAP positive cells (Fig. 1H ).
To assess whether blocking Notch3 expression in osteoblastic tumors enhances lytic lesions, we injected 22Rv1 or C4-2B cells harboring doxycycline-inducible Notch3 shRNA into mouse tibiae. Loss of Notch3 in doxycycline-treated tumors significantly increased osteolytic lesion area over 2-fold ( Fig. 2A) . Loss of Notch3 expression was confirmed by IHC staining (Fig. 2B-C) . Loss of Notch3 also resulted in a 2-fold increase in the number of osteoclasts at the tumor-bone interface (Fig. 2B-C) . Loss of Notch3 had no effect on tumor cell proliferation ( Supplementary Fig. S2C-D) . Thus, expression of active Notch3 in prostate tumors in the bone inhibits osteolytic lesion development independent of tumor proliferation.
Notch3 induces the expression of MMP-3 in prostate cancer bone lesions.
To identify secreted factors that contribute specifically to osteoblastic bone lesion development, we used a human cytokine array to compare subcutaneous tumors versus tibial tumors generated from PC3, C4-2B, or 22Rv1 cells. MMP-3 was specifically elevated in C4-2B 13 and 22Rv1 bone tumors, compared to their subcutaneous tumors (Fig. 3A) . No change in MMP-3 levels was observed between PC3 tumors in the bone versus skin.
To investigate whether Notch3 controls MMP-3 expression, PC3-NICD3, PC3-shN3, or C4-2B-shN3 tibial tumors were analyzed for MMP-3 expression by IHC and qRT-PCR. MMP-3 protein was elevated in the doxycycline-treated PC3-NICD3 tumors relative to sucrose-treated control tumors (Fig. 3B) . Conversely, loss of Notch3 expression in PC3-shN3 or C4-2B-shN3
tumors by doxycycline reduced MMP-3 levels relative to controls (Fig. 3B) . Human-specific MMP-3 mRNA was increased by doxycycline in PC3-NICD3 tumors (Fig. 3C) , and decreased by Notch3 loss in PC3-shN3 and C42B-shN3 tumors ( Fig. 3D-E) . Furthermore, induction of NICD3 in PC3-NICD3 cells induced the secretion of MMP-3 into the conditioned medium (Fig. 3F ).
These results indicate Notch3 induces the expression of MMP-3.
Notch3 in cancer cells changes osteoblast and osteoclast differentiation.
There are two ways in which NICD3, acting in tumor cells, could inhibit osteolytic lesions:
through a decrease in osteoclastogenesis or through an increase in osteoblastogenesis. To evaluate these possibilities, we analyzed expression of osteoclast inhibitors in PC3-NICD3
tumor-bearing tibiae. Mouse-specific IL-10 mRNA, an inhibitor of osteoclastogenesis (33, 34) , is upregulated over 8-fold in doxycycline-treated PC3-NICD3 tumors relative to sucrose-treated controls (Fig. 4A ). In addition, the ratio of mouse-specific OPG/RANKL mRNA is elevated over 2-fold in PC3-NICD3 tibiae (Fig. 4B) , which limits osteoclastogenesis (35) . This increase in osteoclastogenesis inhbitors by NICD3 in vivo supports the decrease in TRAP staining (i.e.
active osteoclasts) seen around the NICD3-expressing tumors (see Fig. 1F ). Conversely, there was a corresponding significant 5-8-fold increase in osteoblast markers, bone sialoprotein (BSP), osteocalcin (OCN), and alkaline phosphatase (ALP) (Fig 4C) , in the doxycycline-treated PC3-NICD3 tumors. Thus, NICD3 expression in tumors leads to both increased osteoblastogenesis and decreased osteoclastogenesis.
To more directly measure the effect of the NICD3-expressing tumor cells on osteoblasts, conditioned medium (CM) from doxycycline-treated PC3-NICD3 cells was added to differentiating osteoblasts in vitro. CM from doxycycline-stimulated PC3-NICD3 cells enhanced osteoblast differentiation as measured by increased alkaline phosphatase (ALP) staining and increased colony formation (Fig. 4D ). This was accompanied by a 3-to 4-fold increase in osteoblast differentiation markers, i.e. Osterix (OSX), BSP, and OCN (Fig. 4E) . CM from doxycycline-treated PC3-NICD3 cells also stimulated osteoblast proliferation (Fig. 4F) and expression of Cyclin A, D and E (Fig. 4G ).
To investigate how Notch3 expression in cancer cells affects osteoclasts, we added CM from doxycycline-treated PC3-NICD3 cells to differentiating osteoclasts. NICD3 CM inhibited the formation of active osteoclasts as measured by the reduced number of fused multinucleated TRAP-positive cells (Fig. 4H ) and reduced mRNA expression of late osteoclast differentiation markers, particularly the calcitonin receptor (Fig. 4I) . Reciprocally, CM from doxycycline-treated C4-2B-shN3 or 22Rv1-shN3 cells stimulated the formation of TRAP-positive multinucleate osteoclasts ( Fig. 4J-K) . Finally, CM from doxycycline-treated C4-2B-NICD3 cells decreased the number of TRAP-positive multinucleate osteoclasts (Fig. 4L) . We did not observe any effects of the CM on osteoclast survival; CM did not induce caspase3 cleave as assessed by immunostaining (not shown). Together these results indicate that CM from Notch3-expressing cells inhibits osteoclast differentiation while simultaneously stimulating osteoblast proliferation and differentiation, leading to a net increase in blastogenesis in Notch3-expressing tumors.
Notch3 inhibits osteolytic bone lesion development in an MMP3-dependent manner.
To determine if Notch3 induction of MMP-3 is responsible for the observed effects of NICD3-CM on osteoblasts and osteoclasts, we directly tested the ability of human recombinant MMP-3 (rMMP3) to regulate differentiation. The addition of rMMP3 to differentiating osteoclasts reduced the formation of TRAP-positive multinucleate cells (Fig. 5A ), but had no effect on osteoblast differentiation as measured by ALP staining (Fig. 5B) . However, rMMP3 did promote osteoblast proliferation (Fig. 5C ).
To investigate the dependency of NICD3 on MMP-3 for its inhibitory effects on osteoclasts, PC3-NICD3 cells were engineered to stably express MMP-3 shRNA (shMMP3).
CM from doxycycline-treated PC3-NICD3-shMMP3 cells rescued the block in TRAP-positive multinucleate cell differentiation induced by CM from doxycycline-treated PC3-NICD3 cells (Fig.   5D ) and prevented the promotion of osteoblast proliferation (Fig. 5E) . We tested whether MMP-3 shRNA could also rescue osteolytic lesion formation. Doxycycline-treated PC3-NICD3-shMMP3 tibial tumors had increased osteolytic lesion area relative to doxycycline-treated PC3-NICD3 (Fig. 5F ). MMP-3 knock-down and NICD3 induction was validated by IHC staining of tibial tumors (Fig. 5G ). While tumor proliferation was decreased ~20% in the PC3-NICD3-shMMP3 tumors relative to PC3-NICD3 tumors, this was independent of NICD3 or shMMP3 expression ( Supplementary Fig. S2E ). Thus, rescue of the osteolytic phenotype occurs independent of tumor proliferation. Altogether, these data indicate MMP-3 is required for
Notch3-mediated inhibition of osteolytic bone lesion development by prostate tumors. (Fig. 6A,B) . Furthermore, there was a significant correlation between expression of Notch3 and MMP-3 in all metastases (Fig. 6C) .
Altogether, our findings indicate that a Notch3-MMP-3 axis plays an integral part in prostate cancer osteoblastic bone metastasis.
DISCUSSION
Our studies demonstrate that Notch3 activation in prostate cancer bone metastases suppresses osteolytic lesions through induction and secretion of MMP-3, which acts to suppress osteoclast differentiation and enhance osteoblast proliferation. Notch3 expression increases with Gleason grade, suggesting its importance in cancer progression (18) . Notch3 is also associated with prostate cancer recurrence (16) . This is the first study to demonstrate that Notch3 is highly expressed in human prostate cancer bone metastases. Interestingly, Notch3 is activated by hypoxia, and bone metastases are highly hypoxic (18, 37) . The hypoxic bone environment could be the driver of elevated Notch3 expression.
The promotion of osteoblast proliferation and differentiation by simply inducing NICD3
expression in an osteolytic cell line, suggests Notch3 is a key regulator of the osteoblastic phenotype that is so unique to prostate cancer. While prostate cancer is highly osteoblastic, there are also underlying osteolytic events (4, 5, 38) . Our findings indicate that elevated Notch3 reduces the osteolytic events through its extrinsic effects on the bone microenvironment, with little to no intrinsic effect on tumor cell proliferation. NICD3 accomplishes this by promoting osteoblastogenesis while simultaneously inhibiting osteoclastogenesis; thus, tipping bone remodeling towards enhanced bone formation. We further found that this osteolytic suppression is MMP3-dependent. MMP-3 is known to promote the cleavage of PTHrP produced by cancer cells, which stimulates osteoblast migration and mineralization in vitro but lacks the osteolytic function associated with full length PTHrP (39) . PTHrP also promotes osteoblast proliferation (40) . Thus, the effects of the Notch3-MMP-3 axis on osteoblasts might depend in part on MMP-3-cleaved PTHrP. A previous study demonstrated that MMP-3 induces osteoclast death (41);
however, we did not detect induction of any caspase-dependent cell death in our in vitro cultures either from NICD3-conditioned medium or by recombinant MMP-3.
This is the first study to demonstrate how MMP-3, secreted from cancer cells, modulates the function of bone cells in prostate cancer bone lesions. MMP-3 expression is higher in primary human prostate tumors compared to PIN and normal tissue (42) , and MMP-3 was previously reported to be elevated in a prostate cancer bone xenograft, but the source or function was not identified (43) . MMP-3 is highly expressed in other cancers like breast, lung, pancreas, and osteocarcome, which correlates with poor patient survival (44, 45) . We are the first to demonstrate elevated MMP-3 expression in human bone metastases, compared to visceral metastases, in prostate cancer patients. Furthermore, Notch3 expression is similarly elevated in bone metastases and correlates with elevated MMP-3 expression.
MMP-3 expression is induced in osteoblasts in response to inflammatory signals or mechanical stress and is necessary for bone remodeling (46, 47) . Thus, tumors that secret MMP-3 may access this normal bone stress response. Interestingly, MMP-3 is elevated in the serum of rheumatoid arthritis patients, which is accompanied by both bone remodeling and inflammation (48) . MMP-3 levels are reportedly higher in the serum of prostate cancer patients with bone metastatic disease (24) . Our data provide mechanistic evidence and clinical relevance of a Notch3-MMP3 axis in prostate cancer osteoblastic bone metastasis.
In the past ten years there have been improvements in the options to treat bone metastatic prostate cancer; however, the available drugs (docetaxel, carbitaxel, abiraterone or enzalutamide) only increase patient survival for a short time as most patients eventually develop resistance to these drugs and finally succumb to the disease (1, 49) . Our data demonstrates that NICD3 modulates the bone microenvironment, but has minimal effects on tumor cell proliferation. This suggests that inhibitors of Notch alone might not be effective at reducing tumor burden. Furthermore, while inhibition of Notch3 activity will decrease osteoblastic lesions, it may enhance lytic lesions by promoting osteoclast function and inhibiting the osteoblasts.
Increasing the function of osteoclasts in osteoblastic metastasis could be an important step towards rebalancing bone homeostasis; however, there will be a need for combinatorial therapy to inhibit the excessive osteolysis caused by Notch inhibition. Bisphosphonates, which inhibit bone destruction by inhibiting osteoclast activity (5), could be used in combination with Notch3 inhibitors to rebalance bone homeostasis. 
